Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : LLY crawled date : 2021 - 06 - 22 save search
TRexBio Chomps Down on $59 Million Series A for Immunobiology
Published: 2021-06-22 (Crawled : 15:00) - biospace.com/
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: -0.08%
H: 0.2%
C: -0.05%
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -0.02%
H: 0.44%
C: -0.53%
TRexBio Closes the Final Tranche of $59 Million Series A Financing to Advance Innovation in Tissue Immunobiology for the treatment of Cancer and Inflammatory Diseases
Published: 2021-06-22 (Crawled : 13:00) - biospace.com/
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: -0.08%
H: 0.2%
C: -0.05%
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -0.02%
H: 0.44%
C: -0.53%
disease treatment cancer
BioCorRx Welcomes Four Experts to Expanded Scientific Advisory Board
Published: 2021-06-22 (Crawled : 13:00) - globenewswire.com
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: -0.08%
H: 0.2%
C: -0.05%
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -0.02%
H: 0.44%
C: -0.53%
expansion
Dicerna Initiates Patient Dosing in ESTRELLA Phase 2 Clinical Trial of Belcesiran for the Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease
Published: 2021-06-22 (Crawled : 12:15) - biospace.com/
NVO | News | $122.71 -0.03% 0.17% 5M
|
Health Technology
|
| O: -0.39%
H: 0.27%
C: -0.21%
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -0.02%
H: 0.44%
C: -0.53%
ALNY | $144.315 -0.58% -0.59% 700K
|
Health Technology
|
| O: 0.08%
H: 1.01%
C: 0.9%
disease liver disease treatment phase 2 liver trial
Innovent Announces the Approval of Pemazyre® (pemigatinib) in Taiwan Market for the Treatment of Adults with Previously Treated, Unresectable Locally Advanced or Metastatic Cholangiocarcinoma with a FGFR2 Fusion or Rearrangement
Published: 2021-06-22 (Crawled : 01:00) - prnewswire.com
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -0.02%
H: 0.44%
C: -0.53%
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: 0.26%
H: 0.99%
C: -0.07%
treatment ev approval
Reviews of Pediatric Studies Conducted under BPCA and PREA from 2012 – present
Published: 2021-06-21 (Crawled : 00:00) - fda.gov
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: 0.18%
H: 1.54%
C: 1.39%
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 0.25%
H: 2.13%
C: 1.63%
BMY | $48.93 1.3% 0.0% 10M
|
Health Technology
|
| O: 0.21%
H: 0.83%
C: 0.33%
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: 0.5%
H: 1.37%
C: 0.91%
XERS | $1.73 -1.7% -1.73% 2M
|
Health Technology
|
| O: 0.24%
H: 0.73%
C: -4.13%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -0.32%
H: 0.17%
C: -0.13%
OTIC | $0.077
|
Health Technology
|
| O: 0.0%
H: 3.98%
C: -1.33%
OMER | $3.045 -5.14% -5.42% 390K
|
Health Technology
|
| O: 1.39%
H: 0.79%
C: 0.33%
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: 0.57%
H: 0.86%
C: 0.54%
BCRX | $4.44 -1.33% -1.35% 4.7M
|
Health Technology
|
| O: 0.5%
H: 4.88%
C: 4.7%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: 0.4%
H: 0.53%
C: 0.25%
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
Your saved searches
Save your searches and get alerts when important news are released.